TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- LNG Energy Group Corp. (TSXV: LNGE) (TSXV: LNGE.WT) (OTCQB: LNGNF) (FWB: E26) (the “Company” or “LNG Energy Group”) announces that, further to the news release dated May 7, 2025, the Ontario Securities Commission (the “OSC”), has notified the Company that it has issued a failure-to-file cease trade order (“FFCTO”), under Multilateral Instrument 11-103 – Failure-to-File Cease Trade Orders in Multiple Jurisdictions against the Company (“MI 11-103”). The FFCTO was issu ...

DELTA RENTAL HOMES DELTA RENTAL HOMES Neinor Homes has sold five rental buildings, totalling 251 housing units for c.€50mn Since 2023, Neinor Homes has sold a total of 1,334 rental units, for c.€325mn with an attractive gross development margin of 24.8% After this disposal, Neinor has successfully concluded its objective to fully crystallize the value of its rental portfolio Including figures from 1Q25, Neinor pre-sold a total of 921 housing units in its strongest ever start of the year MADRID ...

TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”), a developer of confidential computing cybersecurity solutions and services, today announced a series of new customer wins through its cybersecurity division, further expanding its footprint in high-risk, regulated industries including healthcare, financial services, and digital infrastructure. The new engagements, signed over the first quarter of 2025 and collectively valued at over $1.5 milli ...

VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (the “Company”) (TSX:III) reports financial results for the three months ended March 31, 2025. QUARTER HIGHLIGHTS “Imperial delivered solid operating and financial results for the first quarter of 2025”, said Brian Kynoch, President. “Consolidated production totalled 15,842,336 pounds copper and 17,120 ounces gold which was higher by 28% and 33% respectively, compared to the first quarter of 2024. Financially, we achie ...

– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments f ...

Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ...

Core Insights - Inter&Co Inc. reported strong financial results for Q1 2025, highlighting a significant increase in net income and improved efficiency metrics [1][6] - The company emphasizes its commitment to innovation and cost control, which has contributed to its growth and profitability [2][3] Financial Performance - Total clients reached 37.7 million, with 21.6 million active clients and an activation rate of 57.2% [6] - Net income was R$287 million, a 57% increase year-over-year [6] - Return on equity improved to 12.9%, up from 9.2% in Q1 2024 [6] - Efficiency ratio reached 48.8%, improving by 1.3 percentage points compared to Q4 2024 [6] - Non-performing loans (NPLs) over 90 days decreased to 4.1%, down 0.8 percentage points from Q1 2024 [6] Strategic Initiatives - The company is focusing on peer-to-peer payments (Pix) in Brazil and has seen significant uptake in its loyalty program, Loop [2] - The introduction of a new Private Payroll offering aligns with Inter's digital, low-cost distribution model, presenting a key growth opportunity [2]

Core Insights - Farmasiet, Norway's largest online pharmacy, has partnered with Agillic for advanced customer engagement to explore untapped business potential [1][2] - The decision to choose Agillic was driven by the need for a platform that supports advanced ideas while ensuring compliance with European data privacy and security regulations [2][4] - The tailored solution launched by Farmasiet includes eCommerce integration, advanced customer journeys, product feeds, and mobile optimization, completed in just six weeks [3][4] Company Overview - Agillic A/S is a Danish software company listed on Nasdaq First North Growth Market Copenhagen, providing a platform for brands to create, automate, and send personalized communication based on data-driven insights [5] - The company is headquartered in Copenhagen, Denmark, and focuses on enabling brands to engage with millions of customers effectively [5]

Core Points - The Annual Report for Octopus Titan VCT plc for the year ended 31 December 2024 has been made available to shareholders [1] - The report includes the Notice of Meeting for the Annual General Meeting scheduled for 19 June 2025 [1] Submission and Availability - The Annual Report and Form of Proxy have been submitted to the Financial Conduct Authority's Electronic Submission System [2] - The documents are available for inspection at the FCA's National Storage Mechanism [2] - For further inquiries, contact details for Octopus Company Secretarial Services Limited are provided [2]

Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing cellular therapies for life-threatening and chronic aging-related conditions [6] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [6] - Laromestrocel has potential applications across various disease areas, including hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [6] Recent Developments - Longeveron has been selected as a Semi-Finalist Team in the XPRIZE Healthspan competition, receiving a $250,000 Milestone 1 Award [1][2] - The XPRIZE Healthspan competition is a 7-year, $101 million global initiative aimed at revolutionizing the approach to human aging [4] - The competition evaluates teams based on their scientific merit and the feasibility of their therapeutic approaches to restore or preserve functions lost to age-related degradation [2][4] Clinical Trials and FDA Designations - Laromestrocel has shown positive initial results in five clinical trials across three indications: Alzheimer's Disease, aging-related frailty, and HLHS [2] - The development programs for laromestrocel have received five significant U.S. FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for Alzheimer's Disease [2][6] Competition Goals - The XPRIZE Healthspan competition aims to develop therapeutics that can restore muscle, cognitive, and immune function by at least 10 years, with an ambitious goal of extending healthy life by 20 years [2][4] - The competition's top 100 teams were selected from over 600 applicants across 58 countries, with the potential for a grand prize of between $61 million and $81 million for the winning team [2][4]